fenofibrate has been researched along with Cardiac Hypertrophy in 16 studies
Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE
Cardiac Hypertrophy: Enlargement of the HEART due to chamber HYPERTROPHY, an increase in wall thickness without an increase in the number of cells (MYOCYTES, CARDIAC). It is the result of increase in myocyte size, mitochondrial and myofibrillar mass, as well as changes in extracellular matrix.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, it is important to examine whether fenofibrate would modulate the cardiac P450 and its associated arachidonic acid metabolites and whether this modulation protects against isoproterenol-induced cardiac hypertrophy." | 7.80 | Fenofibrate modulates cytochrome P450 and arachidonic acid metabolism in the heart and protects against isoproterenol-induced cardiac hypertrophy. ( Althurwi, HN; El-Kadi, AO; Elshenawy, OH, 2014) |
| "Fenofibrate, a specific peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, was reported to inhibit cardiac hypertrophy." | 7.79 | Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4. ( Chao, X; Chen, J; Geng, B; Le, K; Liu, P; Liu, Z; Luo, J; Xu, S; Ye, J; Zeng, S; Zou, J, 2013) |
| "The present study has been designed to investigate the effects of fenofibrate, a peroxisome proliferator-activated receptor (PPAR)alpha agonist, rosiglitazone, a PPARgamma agonist and the combination of both fenofibrate and rosiglitazone in partial abdominal aortic constriction (PAAC)-induced pathological cardiac hypertrophy in rats." | 7.74 | Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats. ( Balakumar, P; Rose, M; Singh, M, 2007) |
| " In the salt-loaded spontaneously hypertensive stroke-prone rat (SHRSP), a model of cardiac hypertrophy and nephropathy that shows mitochondrial alterations in the myocardium, we evaluated the cardiorenal effects of fenofibrate, a peroxisome proliferator-activated receptor alpha (PPARα) agonist that acts by modulating mitochondrial and peroxisomal fatty acid oxidation." | 3.88 | Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection. ( Abbate, M; Castiglioni, L; Crestani, M; Fiaschè, M; Fiordaliso, F; Foray, C; Gelosa, P; Giudici, M; Guerrini, U; Mitro, N; Pignieri, A; Rottoli, D; Sironi, L; Tremoli, E; Zoja, C, 2018) |
| "Our study shows that fenofibrate may protect against ET-1-induced cardiomyocyte hypertrophy and enhanced adiponectin expression through modulation of PPARα expression in vitro and limitation of daunorubicin cardiotoxicity in vivo, suggesting a novel mechanistic insight into the role of PPARα and adiponectin in cardiac hypertrophy and heart failure." | 3.85 | Endothelin-1-Induced Cell Hypertrophy in Cardiomyocytes is Improved by Fenofibrate: Possible Roles of Adiponectin. ( Chen, JW; Jen, HL; Lin, SJ; Yin, WH, 2017) |
| " Therefore, it is important to examine whether fenofibrate would modulate the cardiac P450 and its associated arachidonic acid metabolites and whether this modulation protects against isoproterenol-induced cardiac hypertrophy." | 3.80 | Fenofibrate modulates cytochrome P450 and arachidonic acid metabolism in the heart and protects against isoproterenol-induced cardiac hypertrophy. ( Althurwi, HN; El-Kadi, AO; Elshenawy, OH, 2014) |
| "Fenofibrate, a specific peroxisome proliferator-activated receptor alpha (PPAR-α) agonist, was reported to inhibit cardiac hypertrophy." | 3.79 | Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4. ( Chao, X; Chen, J; Geng, B; Le, K; Liu, P; Liu, Z; Luo, J; Xu, S; Ye, J; Zeng, S; Zou, J, 2013) |
| "The present study has been designed to investigate the effects of fenofibrate, a peroxisome proliferator-activated receptor (PPAR)alpha agonist, rosiglitazone, a PPARgamma agonist and the combination of both fenofibrate and rosiglitazone in partial abdominal aortic constriction (PAAC)-induced pathological cardiac hypertrophy in rats." | 3.74 | Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats. ( Balakumar, P; Rose, M; Singh, M, 2007) |
| " We investigated its role in angiotensin II-induced hypertension in the Tsukuba hypertensive mouse (THM)." | 3.74 | Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse. ( Bak, S; Coleman, T; Osher, E; Semenkovich, CF; Stern, N; Tordjman, KM; Vechoropoulos, M; Yudovich, R, 2007) |
| "Peroxisome proliferator-activated receptor (PPAR) activation may prevent cardiac hypertrophy and inhibit production of endothelin-1 (ET-1), a hypertrophic agent." | 3.72 | Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension. ( Amiri, F; Diep, QN; Iglarz, M; Paradis, P; Schiffrin, EL; Touyz, RM; Viel, EC, 2003) |
| "The two kinds of cardiac hypertrophy exhibited divergent SCAD changes in myocardial fatty acids utilization." | 1.42 | Changes in short-chain acyl-coA dehydrogenase during rat cardiac development and stress. ( Chen, S; Huang, J; Huang, Q; Liu, P; Lu, Y; Luo, J; Wang, P; Xu, L; Yuan, X; Zhou, S, 2015) |
| "The treatment with fenofibrate or vehicle was started 7 days before the AB operation." | 1.31 | Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. ( Goto, K; Irukayama-Tomobe, Y; Miyauchi, T; Ogata, T; Sakai, S; Yamaguchi, I, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (37.50) | 29.6817 |
| 2010's | 10 (62.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castiglioni, L | 1 |
| Pignieri, A | 1 |
| Fiaschè, M | 1 |
| Giudici, M | 1 |
| Crestani, M | 1 |
| Mitro, N | 1 |
| Abbate, M | 1 |
| Zoja, C | 1 |
| Rottoli, D | 1 |
| Foray, C | 1 |
| Fiordaliso, F | 1 |
| Guerrini, U | 1 |
| Tremoli, E | 1 |
| Sironi, L | 1 |
| Gelosa, P | 1 |
| Zou, J | 2 |
| Le, K | 3 |
| Xu, S | 2 |
| Chen, J | 1 |
| Liu, Z | 1 |
| Chao, X | 1 |
| Geng, B | 1 |
| Luo, J | 3 |
| Zeng, S | 1 |
| Ye, J | 1 |
| Liu, P | 5 |
| Althurwi, HN | 1 |
| Elshenawy, OH | 1 |
| El-Kadi, AO | 1 |
| Huang, Q | 2 |
| Huang, J | 2 |
| Zeng, Z | 1 |
| Chen, S | 2 |
| Liu, B | 1 |
| Pan, X | 1 |
| Zang, L | 1 |
| Zhou, S | 2 |
| Xu, L | 1 |
| Yuan, X | 1 |
| Lu, Y | 1 |
| Wang, P | 2 |
| Ismael, S | 1 |
| Purushothaman, S | 1 |
| Harikrishnan, VS | 1 |
| Nair, RR | 1 |
| Wu, Y | 1 |
| Wang, BX | 1 |
| Guo, YY | 1 |
| Wang, YQ | 1 |
| Jen, HL | 1 |
| Yin, WH | 1 |
| Chen, JW | 1 |
| Lin, SJ | 1 |
| Huang, Y | 1 |
| Zhang, H | 2 |
| Shao, Z | 1 |
| O'Hara, KA | 1 |
| Kopilas, MA | 1 |
| Yu, L | 1 |
| Netticadan, T | 1 |
| Anderson, HD | 1 |
| Li, R | 2 |
| Wu, X | 1 |
| Huang, H | 1 |
| Bao, Y | 1 |
| Cai, Y | 1 |
| Lan, T | 1 |
| Moss, J | 1 |
| Li, C | 1 |
| Shen, X | 1 |
| Ogata, T | 1 |
| Miyauchi, T | 1 |
| Sakai, S | 1 |
| Irukayama-Tomobe, Y | 1 |
| Goto, K | 1 |
| Yamaguchi, I | 1 |
| Iglarz, M | 1 |
| Touyz, RM | 1 |
| Viel, EC | 1 |
| Paradis, P | 1 |
| Amiri, F | 1 |
| Diep, QN | 1 |
| Schiffrin, EL | 1 |
| Rose, M | 1 |
| Balakumar, P | 1 |
| Singh, M | 1 |
| Zheng, W | 1 |
| Pi, R | 1 |
| Gao, J | 1 |
| Tordjman, KM | 1 |
| Semenkovich, CF | 1 |
| Coleman, T | 1 |
| Yudovich, R | 1 |
| Bak, S | 1 |
| Osher, E | 1 |
| Vechoropoulos, M | 1 |
| Stern, N | 1 |
| Force, T | 1 |
16 other studies available for fenofibrate and Cardiac Hypertrophy
| Article | Year |
|---|---|
Fenofibrate attenuates cardiac and renal alterations in young salt-loaded spontaneously hypertensive stroke-prone rats through mitochondrial protection.
Topics: Acyl-CoA Dehydrogenase; Animals; Cardiomegaly; Cellular Senescence; Fenofibrate; Gene Expression; Hy | 2018 |
Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-activated receptor-α partly via preventing p65-NFκB binding to NFATc4.
Topics: Angiotensin II; Animals; Cardiomegaly; Cells, Cultured; Enzyme Activation; Fenofibrate; Hypolipidemi | 2013 |
Fenofibrate modulates cytochrome P450 and arachidonic acid metabolism in the heart and protects against isoproterenol-induced cardiac hypertrophy.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Arachidonic Acid; Cardiomegaly; Cytochrome P-450 CYP2J2; Cytoc | 2014 |
Effects of ERK1/2/PPARα/SCAD signal pathways on cardiomyocyte hypertrophy induced by insulin-like growth factor 1 and phenylephrine.
Topics: Animals; Animals, Newborn; Butyryl-CoA Dehydrogenase; Cardiomegaly; Disease Models, Animal; Fatty Ac | 2015 |
Changes in short-chain acyl-coA dehydrogenase during rat cardiac development and stress.
Topics: Animals; Animals, Newborn; Blood Pressure; Butyryl-CoA Dehydrogenase; Cardiomegaly; Disease Models, | 2015 |
Ligand specific variation in cardiac response to stimulation of peroxisome proliferator-activated receptor-alpha in spontaneously hypertensive rat.
Topics: Acyl-CoA Dehydrogenase; Animals; Blood Pressure; Cardiomegaly; Fenofibrate; Gene Expression; Hyperte | 2015 |
[The effect of relgulation of PPAR-α on cardiac hypertrophy and the relationship between the effect of PPAR-α with PI3K/Akt/mTOR pathway].
Topics: Atrial Natriuretic Factor; Cardiomegaly; Cells, Cultured; Fenofibrate; Humans; Isoproterenol; Myocyt | 2015 |
Endothelin-1-Induced Cell Hypertrophy in Cardiomyocytes is Improved by Fenofibrate: Possible Roles of Adiponectin.
Topics: Adiponectin; Animals; Animals, Newborn; Cardiomegaly; Endothelin-1; Fenofibrate; Humans; Hypolipidem | 2017 |
Suppression of endothelin-1-induced cardiac myocyte hypertrophy by PPAR agonists: role of diacylglycerol kinase zeta.
Topics: Age Factors; Animals; Animals, Newborn; Cardiomegaly; Cells, Cultured; Chromans; Diacylglycerol Kina | 2011 |
PPARα activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4.
Topics: Animals; Cardiomegaly; Cell Nucleus; Dose-Response Relationship, Drug; Endothelin-1; Fenofibrate; GA | 2012 |
Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts.
Topics: Animals; Cardiomegaly; Collagen Type I; Collagen Type III; Endomyocardial Fibrosis; Endothelin-1; Fe | 2002 |
Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Collagen; Desoxycorticosterone; Endothelin-1; En | 2003 |
Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.
Topics: Analysis of Variance; Animals; Aorta, Abdominal; Blood Pressure; Cardiomegaly; Collagen; Constrictio | 2007 |
Activation of peroxisome proliferator-activated receptor-alpha prevents glycogen synthase 3beta phosphorylation and inhibits cardiac hypertrophy.
Topics: Animals; Animals, Newborn; Cardiomegaly; Cell Nucleus; Cells, Cultured; Endothelin-1; Fenofibrate; G | 2007 |
Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse.
Topics: Aldosterone; Angiotensin II; Animals; Atherosclerosis; Blood Pressure; Cardiomegaly; Diet, Atherogen | 2007 |
The weakness of a big heart.
Topics: Cardiomegaly; Casein Kinase II; Cyclin-Dependent Kinase Inhibitor p27; Fenofibrate; Humans; Myocytes | 2008 |